Park Place Capital Corp Sells 52 Shares of Danaher Co. (NYSE:DHR)

Park Place Capital Corp reduced its position in Danaher Co. (NYSE:DHR) by 4.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,046 shares of the conglomerate’s stock after selling 52 shares during the quarter. Park Place Capital Corp’s holdings in Danaher were worth $240,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC boosted its position in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. raised its holdings in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after buying an additional 397,671 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its position in shares of Danaher by 82.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock worth $181,651,000 after buying an additional 295,187 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $244.19 on Thursday. The firm has a market cap of $176.38 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 4.30 and a beta of 0.83. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average price of $234.84 and a 200 day moving average price of $253.53.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the company earned $2.02 EPS. Danaher’s revenue was up 3.1% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.49 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DHR. Barclays lowered their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. UBS Group cut their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Scotiabank started coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.